Exhibit 99.1


graphic
GH RESEARCH PLC

Unaudited condensed consolidated interim statement of comprehensive loss


 
   
Three months ended
September 30,
   
Nine months ended
September 30,
 
          2026
    2025
    2026
    2025
 

  Note     $’000     $’000     $’000     $’000  
Operating expenses
                                     
Research and development
  3      
(10,071
)
   
(10,567
)
    (34,849 )     (27,377 )
General and administration
  3      
(5,285
)
   
(5,998
)
    (18,711 )     (16,624 )
Loss from operations
         
(15,356
)
   
(16,565
)
    (53,560 )     (44,001 )
                                       
Finance income
 
4
     
2,992
     
2,783
      7,843       8,616  
Finance expense
 
4
     
(75
)
   
(21
)
    (242 )     (373 )
Movement of expected credit loss
         
4
     
30
      12       24  
Foreign exchange (loss)/gain
         
(15
)
   
(247
)
    (616 )     1,613  
Total other income
         
2,906
     
2,545
      6,997       9,880  
                                       
Loss before tax
         
(12,450
)
   
(14,020
)
    (46,563 )     (34,121 )
Tax charge/(credit)
         
-
     
-
      -       -  
Loss for the period
         
(12,450
)
   
(14,020
)
    (46,563 )     (34,121 )
                                       
Other comprehensive (expense)/income
                                     
Items that may be reclassified to profit or loss
                                     
Fair value movement on marketable securities
         
(38
)
   
(33
)
    (167 )     (55 )
Currency translation adjustment
         
(52
)
   
(63
)
    (1,791 )     926  
Total comprehensive loss for the period
         
(12,540
)
   
(14,116
)
    (48,521 )     (33,250 )
                                       
Attributable to owners:
                                     
Loss for the period
         
(12,450
)
   
(14,020
)
    (46,563 )     (34,121 )
Total comprehensive loss for the period
         
(12,540
)
   
(14,116
)
    (48,521 )     (33,250 )
                                       
Loss per share
                                     
Basic and diluted loss per share (in USD)
 
15
     
(0.18
)
   
(0.23
)
    (0.71 )     (0.56 )

 The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
1

graphic
GH RESEARCH PLC

Unaudited condensed consolidated interim statement of financial position
 

         
At September 30,
   
At December 31,
 
            2026
    2025
 
      Note    
$’000
   
$’000
 
ASSETS
                         
Current assets
                         
Cash and cash equivalents
   
5
     
345,088
     
246,251
 
Marketable securities
   
6
     
5,501
     
34,457
 
Other current assets
   
7
     
6,523
     
5,268
 
Total current assets
             
357,112
     
285,976
 
Non-current assets
                         
Property, plant and equipment
             
519
     
620
 
Other non-current assets
    8
      2,281       1,634  
Total non-current assets
             
2,800
     
2,254
 
Total assets
             
359,912
     
288,230
 
                           
LIABILITIES AND EQUITY
                         
Current liabilities
                         
Trade payables
    9      
5,339
     
3,773
 
Lease liability
             
283
     
365
 
Other current liabilities
    10      
5,263
     
4,242
 
Total current liabilities
             
10,885
     
8,380
 
Non-current liabilities
                         
Lease liability
             
7
     
147
 
Total non-current liabilities
             
7
     
147
 
Total liabilities
             
10,892
     
8,527
 
                           
Equity attributable to owners
                         
Share capital
             
1,717
     
1,551
 
Additional paid-in capital
             
542,946
     
431,061
 
Other reserves
             
17,909
     
13,292
 
Foreign currency translation reserve
             
(13,567
)
   
(11,776
)
Accumulated deficit
             
(199,985
)
   
(154,425
)
Total equity
             
349,020
     
279,703
 
Total liabilities and equity
             
359,912
     
288,230
 

 The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
2

graphic
GH RESEARCH PLC

Unaudited condensed consolidated interim statement of changes in equity
 

 
Attributable to owners
 

 
Share capital
   
Additional
paid-in
capital
   
Other
reserves
   
Foreign
currency
translation
reserve
   
Accumulated
deficit
   
Total
 

 
$’000
   
$’000
   
$’000
   
$’000
   
$’000
   
$’000
 
At January 1, 2025
   
1,301
     
291,463
     
5,194
     
(12,561
)
   
(106,446
)
   
178,951
 
Loss for the period
   
-
     
-
     
-
     
-
     
(34,121
)
   
(34,121
)
Other comprehensive (expense)/income
   
-
     
-
     
(55
)
   
926
     
-
      871
 
Total comprehensive loss for the period
   
-
     
-
     
(55
)
   
926
     
(34,121
)
   
(33,250
)
Share-based compensation expense
   
-
     
-
     
5,848
     
-
     
-
     
5,848
 
Transfer of share options
    -       -       (269 )     -       269       -  
Share option exercises
    -       -       (10 )     -       10       -  
Issue of share capital
    250       139,598       -       -       -       139,848  
Total transactions with owners
   
250
     
139,598
     
5,569
     
-
     
279
     
145,696
 
At September 30, 2025
   
1,551
     
431,061
     
10,708
     
(11,635
)
   
(140,288
)
   
291,397
 
                                                 
At January 1, 2026
   
1,551
     
431,061
     
13,292
     
(11,776
)
   
(154,425
)
   
279,703
 
Loss for the period
   
-
     
-
     
-
     
-
     
(46,563
)
   
(46,563
)
Other comprehensive expense
   
-
     
-
     
(167
)
   
(1,791
)
   
-
     
(1,958
)
Total comprehensive loss for the period
   
-
     
-
     
(167
)
   
(1,791
)
   
(46,563
)
   
(48,521
)
Share-based compensation expense
   
-
     
-
     
5,787
     
-
     
-
     
5,787
 
Transfer of share options
    -       -       (1,003 )     -       1,003       -  
Share option exercises
    3       811       -       -       -       814  
Issue of share capital
    163
      111,074       -       -
      -       111,237  
Total transactions with owners
   
166
     
111,885
     
4,784
     
-
     
1,003
     
117,838
 
At September 30, 2026
   
1,717
     
542,946
     
17,909
     
(13,567
)
   
(199,985
)
   
349,020
 

 The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
3

graphic
GH RESEARCH PLC

Unaudited condensed consolidated interim statement of cash flows
 
   
Nine months ended
September 30,
 
    2026
    2025
 
   
$’000
   
$’000
 
Cash flows from operating activities
               
Loss for the period
   
(46,563
)
   
(34,121
)
Depreciation
   
275
     
247
 
Share-based compensation expense
   
5,787
     
5,848
 
Finance income
   
(7,843
)
   
(8,616
)
Finance expense
   
242
     
373
 
Movement of expected credit loss
   
(12
)
   
(24
)
Foreign exchange loss/(gain)
   
616
     
(1,613
)
Movement in working capital
   
564
     
(1,533
)
Cash flows used in operating activities
   
(46,934
)
   
(39,439
)
Finance expense paid
   
(166
)
   
(460
)
Finance income received
   
10,763
     
8,677
 
Net cash used in operating activities
   
(36,337
)
   
(31,222
)
                 
Cash flows from investing activities
               
Purchase of property, plant and equipment
   
(101
)
   
(102
)
Proceeds from sale of other financial assets
    -       19,585  
Proceeds from redemptions and disposals of marketable securities
    25,866       17,849  
Cash flows from investing activities
   
25,765
     
37,332
 
                 
Cash flows from financing activities
               
Proceeds from share issuances
   
118,314
      150,000  
Transaction costs from share issuances
    (6,263 )     (10,152 )
Payment of lease liability
    (211 )     (129 )
Net cash flows from financing activities
    111,840       139,719  
                 
Net increase in cash and cash equivalents
   
101,268
     
145,829
 
Cash and cash equivalents at the beginning of the period
   
246,251
     
100,791
 
Impact of foreign exchange on cash and cash equivalents
   
(2,431
)
   
3,034
 
Cash and cash equivalents at the end of the period
   
345,088
     
249,654
 

 The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
4

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1.
Corporate information

GH Research PLC (the “Company”) was incorporated on March 29, 2021. The registered office of the Company is located at Joshua Dawson House, Dawson Street, Dublin 2, Ireland. The Company and its subsidiaries form the GH Research Group (the “Group” or “GH Research”).

The Company is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Its initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with Treatment Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate and GH002, a proprietary intravenous mebufotenin product candidate.

In April 2026, the Group completed an underwritten offering of its ordinary shares. The net proceeds of the offering were $111.2 million, after deducting underwriting discounts and directly attributable transaction costs.

These unaudited condensed consolidated interim financial statements were presented to the board of directors and approved by them for issue on November 13, 2026.

2.
Basis of preparation, significant judgments, and accounting policies

Basis of preparation

Compliance with IFRS Accounting Standards
The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2026, have been prepared in accordance with IAS 34 “Interim Financial Reporting”. The unaudited condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025, which were prepared in accordance with IFRS Accounting Standards as adopted by the International Accounting Standards Board (“IASB”). These unaudited condensed consolidated interim financial statements are presented in U.S. dollar (“USD” or “$”), which is the Company’s functional currency and the Group’s presentation currency.

The financial information presented in this interim report does not represent full statutory accounts as defined by the Companies Act 2014. The statutory accounts of the Company for the year ended December 31, 2025, are expected to be filed with the Companies Registration Office by November 26, 2026.

New and amended IFRS standards
There are no new IFRS Accounting standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2026, that are relevant to the Group and that have had any material impact in the interim period. The review of the impact of new standards on the Group’s financial statements, which are not yet effective and which have not been early adopted by the Group is ongoing. This includes IFRS 18 “Presentation and Disclosure in Financial Statements”. IFRS 18 will replace IAS 1 “Presentation of financial statements”, introducing new requirements that will help to achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users. Management is currently assessing the detailed implications of applying the new standard on the Group’s financial statements.


5

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
Going concern basis
GH Research is a clinical-stage biopharmaceutical company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. Research and development expenses have been incurred from the start of the Group’s activities, generating negative cash flows from operating activities since formation.

Since its incorporation, the Group has funded its growth through capital increases. The Group has no bank loans or other debt outstanding, except lease liabilities, as of September 30, 2026. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans.

As of September 30, 2026, the Group’s cash and cash equivalents amounted to $345.1 million (December 31, 2025: $246.3 million). The Group also held marketable securities of $5.5 million as of September 30, 2026, (December 31, 2025: marketable securities of $34.5 million). The marketable securities held by the Group are quoted in active markets and are an additional source of liquidity.

The Board of Directors believes that the Group has sufficient financial resources available to cover its planned cash outflows for at least the next twelve months from the date of issuance of these unaudited condensed consolidated interim financial statements. The Group, therefore, continues to adopt the going concern basis in preparing its unaudited condensed consolidated interim financial statements.

Use of estimates and judgments
The preparation of the unaudited condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these unaudited condensed consolidated interim financial statements, the significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty are consistent with those that applied in the preparation of the consolidated financial statements for the year ended December 31, 2025.


Accounting policies
The accounting policies, presentation and methods of computation followed in the unaudited condensed consolidated interim financial statements are consistent with those applied in the Group’s most recent annual financial statements and have been applied consistently to all periods presented in the unaudited condensed consolidated interim financial statements.

Current and deferred income tax
The interim income tax expense is calculated based on the Company’s estimate of the weighted average effective annual income tax rate expected for the full year. The current and deferred income tax charge was $nil for the three and nine months ended September 30, 2026 and 2025, which is in line with the Company’s estimate for the full year. No deferred tax assets have been recognized as there is no certainty that sufficient taxable profits will be generated within the required timeframe to be able to utilize these tax loss carry-forwards in full.

Segment reporting
Management considers the Group to have only a single segment: Research and Development (“R&D”). This is consistent with the way that information is reported internally within the Group for the purpose of allocating resources and assessing performance.


6

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
3.
Expenses by nature

The following table provides the consolidated statement of comprehensive loss classification of our expense by nature:
 
   
Three months ended
September 30,
   
Nine months ended
September 30,
 
   
2026
   
2025
    2026
    2025
 
   
$’000
   
$’000
   
$’000
   
$’000
 
External research and development expenses1
   
6,377
     
7,076
      23,163       18,644  
Employee expenses2, 5
   
3,694
     
3,491
      11,686       8,733  
Total research and development expenses3
   
10,071
     
10,567
      34,849       27,377  
                                 
External costs1
   
3,223
     
3,694
      12,463       10,402  
Employee expenses4, 5
   
2,062
     
2,304
      6,248       6,222  
Total general and administrative expenses3
   
5,285
     
5,998
      18,711       16,624  
Total operating expenses
   
15,356
     
16,565
      53,560       44,001  

1 Includes depreciation expense.

2 Included in employee expenses is share-based compensation expense of $0.9 million and $3.1 million for the three and nine months ended September 30, 2026, respectively, relating to employees in the research and development department (three and nine months ended September 30, 2025, expense of $1.1 million and $2.7 million, respectively).
 
3 Depreciation and other expenses have been reclassified to external research and development expenses and depreciation has been reclassified to external costs for all periods presented as it provides more relevant information.
  
4 Included in employee expenses is share-based compensation expense of $0.9 million and $2.7 million for the three and nine months ended September 30, 2026, respectively, relating to employees in the general and administrative department (three and nine months ended September 30, 2025, expense of $1.2 million and $3.2 million, respectively).

5 Includes termination expenses incurred.

Foreign exchange loss/gain


Foreign exchange loss of $15 thousand for the three months ended September 30, 2026 (loss of $0.2 million for the three months ended September 30, 2025), and foreign exchange loss of $0.6 million for the nine months ended September 30, 2026 (gain of $1.6 million for the nine months ended September 30, 2025) consists primarily of gains and losses related to the translation of the Group’s assets and liabilities from their denominated currencies into the functional currency of each entity, and included the strengthening of the U.S. dollar in the period.


7

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
4.
Finance income and expense

 
 
Three months ended
September 30,
   
Nine months ended
September 30,
 
 
 
2026
   
2025
    2026
    2025
 
 
 
$’000
   
$’000
    $’000
    $’000
 
Finance income
                           
Finance income on cash, cash equivalents and other financial assets
    317       387       1,457       2,275  
Gain on cash equivalents and other financial assets at fair value through profit and loss (“FVTPL”)
   
2,528
     
1,782
      5,664       4,346  
Interest income under effective interest rate method at fair value through other comprehensive income (“FVOCI”)
   
147
     
614
      722       1,995  
Finance income
   
2,992
     
2,783
      7,843       8,616  
 
                               
Finance expense
                               
Finance expense on investments
   
(70
)
   
(13
)
    (225 )     (346 )
Finance expense on lease liability
   
(5
)
   
(8
)
    (17 )     (27 )
Finance expense
   
(75
)
   
(21
)
    (242 )     (373 )

5.
Cash and cash equivalents

        September 30,
        December 31,
   
    2026
    2025
 
    $’000     $’000
 
Cash at bank and in hand
    32,420      
30,972
 
Cash equivalents
    312,668      
215,279
 
      345,088      
246,251
 

During the nine months ended September 30, 2026, proceeds of $29.2 million were received from the redemption of marketable securities, which includes accrued interest. On redemption of the marketable securities, the funds are invested in cash equivalents.


8

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
6.
Marketable securities


 
Marketable
securities
 
   
$’000
 
Fair value
       
At January 1, 2026
   
34,457
 
Accrued interest
   
722
 
Interest received
   
(301
)
Redemptions and disposals of marketable securities
    (29,222 )
Revaluation adjustment
   
(155
)
At September 30, 2026
   
5,501
 

At September 30, 2026, the Group’s marketable securities mature within the next year.

The movement through other comprehensive income (“OCI”) for the three and nine months ended September 30, 2026, and September 30, 2025, is shown in the table below:
 
 
Three months ended
September 30,
   
Nine months ended
September 30,
 
    2026     2025     2026
    2025
 
    $’000     $’000     $’000     $’000  
Revaluation adjustments
    (34 )     (3 )     (155 )     (31 )
Movement of expected credit losses on assets measured at FVOCI
    (4 )     (30 )     (12 )     (24 )
Movement on marketable securities through OCI
    (38 )     (33 )     (167 )     (55 )

7.
Other current assets


Other current assets primarily represent prepayments and research and development tax credit receivable.

8.
Other non-current assets


Other non-current assets represent research and development tax credit receivable.

9.
Trade payables

Trade payables primarily represent amounts incurred for the provision of manufacturing, research and consulting services and professional fees, which are outstanding at the end of the period. Trade payables are due to be settled at different times within 12 months.

10.
Other current liabilities

Other current liabilities primarily represent accruals for operating expenses and employee tax payable and are expected to be settled within one year.


9

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
11.
Share capital


   
Number of
outstanding
shares
 
At December 31, 2025
   
62,029,395
 
Share issue from offering
    6,527,779
 
Share option exercise1
    118,734  
At September 30, 2026
   
68,675,908
 

1 See Note 13

In April 2026, the Group completed an underwritten offering of its ordinary shares in which it issued and sold an aggregate of 6,527,779 ordinary shares at a price of $18.00 per share. The net proceeds of the underwritten offering were $111.2 million, after deducting underwriting discounts and directly attributable transaction costs.
12.
Contingencies

As of September 30, 2026, there were no material contingencies which required adjustment or disclosure in the unaudited condensed consolidated interim financial statements (2025: none).

13.
Share based compensation
 
Share Options
In June 2021, the Company adopted a share option plan referred to herein as the Share Option Plan under which grants of options are made to eligible participants. The Company initially reserved 1,202,734 ordinary shares for future issuance under the Share Option Plan, which includes ordinary shares pursuant to share-based equity awards issued to date. As of September 30, 2026, the total number of ordinary shares which may be issued under the Share Option Plan was 3,721,251 and the Company has 770,444 ordinary shares available for the future issuance of share-based equity awards.

Under the Share Option Plan, the options may be settled only in ordinary shares of the Company. Therefore, the grants of share options under the Share Option Plan have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants.
 

During the three and nine months ended September 30, 2026, the Company granted the option to purchase 215,409 and 434,459 ordinary shares which were in line with the general terms of the Share Option Plan. Of the share options granted in the three and nine months ended September 30, 2026, 180,000 and 329,450 share options, respectively, were granted which vest 25% on the first anniversary of the date of the grant, and thereafter evenly on a monthly basis over the subsequent three years. The contractual term (expiration) of these share options is seven years from the grant date with an exercise price of $0.0251.  Of the share options granted in the three and nine months ended September 30, 2026, the Company granted the option to purchase 8,909 ordinary shares which vested on the date of grant and are subject to a two year service condition. These share options have a contractual term (expiration) of seven years from the grant date with an exercise price of $0.025 per share1. All other share options granted during the three and nine months ended September 30, 2026, 26,500 and 96,100, respectively, vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years and are subject to a two-year service condition. The contractual term (expiration) of these share options is eight years from the grant date with an exercise price of the closing market price on the day prior to the grant.

1 Includes grants to members of key management of the Group.


10

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)

The following table summarizes the share option awards outstanding as of September 30, 2026:
 
   
Average exercise
price per share
in
USD
   
Number of
awards
   
Weighted
average
remaining
life
in years
 
At December 31, 2025
   
3.87
     
2,594,914
     
5.91
 
Granted
   
4.28
     
434,459
     
6.85
 
Forfeited/Expired
   
5.39
     
(87,112
)
   
6.00
 
Exercised1
    6.85       (118,734 )     4.89  
At September 30, 20262
   
3.76
     
2,823,527
     
5.40
 

1 The weighted average share price of share options exercised was $22.00.
2 1,132,261 of the awards outstanding as of September 30, 2026, were exercisable.
 
The weighted average grant date fair value of awards granted during the three and nine months ended September 30, 2026, was $27.24 and $20.23 per award, respectively.

The fair values of the options granted were determined on the date of the grant using the Black-Scholes option-pricing model. The fair values of the options granted during the three and nine months ended September 30, 2026, were determined on the date of the grant using the following assumptions:

   
Three months ended
  September 30, 2026
   
Nine months ended
  September 30, 2026
 
Share price, in USD
   
25.35 - 29.08
     
13.03 - 29.08
 
Strike price, in USD (weighted average)
   
3.33
     
4.28
 
Expected volatility
   
80% - 83%

   
80% - 88%

Award life (weighted average)
   
5.5
     
5.6
 
Expected dividends
   
-
     
-
 
Risk-free interest rate
   
4.36% - 4.61%

   
3.79% - 4.61%

 
The expected volatility for the three months ended September 30, 2026, is based on a blended rate of historical volatility observed among other comparable public companies and the Company’s own historical volatility.

The award life is based on the time interval between the date of grant and the date during the life of the share option after which, when making the grant, the Company expected on average that participants would exercise their options.


As of September 30, 2026, Other Reserves within equity includes $17.9 million (December 31, 2025: $13.1 million) relating to the Group’s Share Option Plan. Balances which relate to forfeited awards which had previously vested or awards which have been exercised are transferred from Other Reserves to Accumulated Deficit. The amount of expense for all awards recognized for services received during the three months ended September 30, 2026, was $1.8 million (three months ended September 30, 2025: $2.3 million) and for the nine months ended September 30, 2026, was $5.8 million (nine months ended September 30, 2025: $5.8 million).

14.
Related party disclosures

There have been no transactions with related parties, other than share options granted to members of key management of 108,909, as of September 30, 2026, that had a material effect on the financial position or performance of the Group (2025: none).


11

graphic
GH RESEARCH PLC
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (continued)
15.
Loss per share


 
Three months ended
September 30,
   
Nine months ended
September 30,
 
   
2026
    2025     2026
    2025
 
Loss attributable to shareholders (in $’000)
   
(12,450
)
   
(14,020
)
    (46,563 )     (34,121 )
Weighted average number of shares in issue
    68,656,960      
62,029,395
      65,766,044       60,710,082  
Basic and diluted loss per share (in USD)
   
(0.18
)
   
(0.23
)
    (0.71 )     (0.56 )

For the three months and the nine months ended September 30, 2026, and 2025, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Share Option Plan, as the effect of including those shares would be anti-dilutive.

16.
Events after the reporting date

There were no events after the reporting date requiring disclosure in the Group’s unaudited condensed consolidated interim financial statements.

12